[go: up one dir, main page]

HUE067983T2 - Bridged tricyclic carbamoylpyridone compounds and uses thereof - Google Patents

Bridged tricyclic carbamoylpyridone compounds and uses thereof

Info

Publication number
HUE067983T2
HUE067983T2 HUE23203855A HUE23203855A HUE067983T2 HU E067983 T2 HUE067983 T2 HU E067983T2 HU E23203855 A HUE23203855 A HU E23203855A HU E23203855 A HUE23203855 A HU E23203855A HU E067983 T2 HUE067983 T2 HU E067983T2
Authority
HU
Hungary
Prior art keywords
bridged tricyclic
carbamoylpyridone compounds
carbamoylpyridone
compounds
tricyclic
Prior art date
Application number
HUE23203855A
Other languages
Hungarian (hu)
Inventor
Hang Chu
Buenrostro Ana Z Gonzalez
Xiaochun Han
Anna E Hurtley
Lan Jiang
Jiayao Li
Gregg M Schwarzwalder
Devleena M Shivakumar
Bargen Matthew J Von
Qiaoyin Wu
Hong Yang
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of HUE067983T2 publication Critical patent/HUE067983T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HUE23203855A 2022-04-06 2023-04-05 Bridged tricyclic carbamoylpyridone compounds and uses thereof HUE067983T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263328061P 2022-04-06 2022-04-06
US202263476873P 2022-12-22 2022-12-22

Publications (1)

Publication Number Publication Date
HUE067983T2 true HUE067983T2 (en) 2024-12-28

Family

ID=86330110

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE23203855A HUE067983T2 (en) 2022-04-06 2023-04-05 Bridged tricyclic carbamoylpyridone compounds and uses thereof
HUE23722475A HUE067768T2 (en) 2022-04-06 2023-04-05 Bridged tricyclic carbamoylpyridone compounds and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE23722475A HUE067768T2 (en) 2022-04-06 2023-04-05 Bridged tricyclic carbamoylpyridone compounds and uses thereof

Country Status (26)

Country Link
US (3) US12024528B2 (en)
EP (3) EP4305034B1 (en)
JP (3) JP7668428B2 (en)
KR (1) KR20250002321A (en)
CN (2) CN120081853A (en)
AU (3) AU2023249631B2 (en)
CA (1) CA3245817A1 (en)
CL (3) CL2024002988A1 (en)
CO (1) CO2024013492A2 (en)
CR (1) CR20240405A (en)
DK (2) DK4310087T3 (en)
DO (1) DOP2024000195A (en)
ES (2) ES2992835T3 (en)
FI (2) FI4305034T3 (en)
HR (2) HRP20240986T1 (en)
HU (2) HUE067983T2 (en)
IL (1) IL315684A (en)
LT (2) LT4310087T (en)
MX (1) MX2024011695A (en)
PE (3) PE20250151A1 (en)
PL (2) PL4305034T3 (en)
PT (2) PT4305034T (en)
SI (2) SI4305034T1 (en)
TW (3) TWI856796B (en)
WO (1) WO2023196875A1 (en)
ZA (2) ZA202406990B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3212105B1 (en) 2014-10-27 2025-09-24 Intuitive Surgical Operations, Inc. System for monitoring control points during reactive motion
KR102781726B1 (en) 2014-10-27 2025-03-18 인튜어티브 서지컬 오퍼레이션즈 인코포레이티드 System and method for integrated surgical table motion
TW202544011A (en) 2019-03-22 2025-11-16 美商基利科學股份有限公司 Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
JP7453399B2 (en) 2020-02-24 2024-03-19 ギリアード サイエンシーズ， インコーポレイテッド Tetracyclic compounds and their use for treating HIV infection
KR20230079137A (en) 2020-09-30 2023-06-05 길리애드 사이언시즈, 인코포레이티드 Crosslinked Tricyclic Carbamoylpyridone Compounds and Uses Thereof
PL4196479T3 (en) 2021-01-19 2024-03-18 Gilead Sciences, Inc. Substituted pyridotriazine compounds and uses thereof
WO2025080879A1 (en) * 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025080850A1 (en) * 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025080863A1 (en) * 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202525289A (en) * 2023-12-22 2025-07-01 美商基利科學股份有限公司 Methods and intermediates for preparing therapeutic compounds

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
AU8294101A (en) 2000-07-21 2002-02-05 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
US7429565B2 (en) 2003-04-25 2008-09-30 Gilead Sciences, Inc. Antiviral phosphonate analogs
HRP20070078A2 (en) 2004-07-27 2007-05-31 Gilead Sciences PHOSPHONATE ANALYSIS OF HIV INHIBITING COMPOUNDS
WO2006088173A1 (en) 2005-02-21 2006-08-24 Shionogi & Co., Ltd. Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity
CN101146811B (en) 2005-03-31 2012-01-11 P.安杰莱蒂分子生物学研究所 Hiv integrase inhibitors
BRPI0610030B8 (en) 2005-04-28 2022-01-11 Glaxosmithkline Llc Compound, pharmaceutical composition, and use of a compound
JP2006342115A (en) 2005-06-10 2006-12-21 Shionogi & Co Ltd Polycyclic compound having hiv integrase inhibition activity
EP1910363A4 (en) 2005-08-04 2010-05-26 Glaxosmithkline Llc Hiv integrase inhibitors
TWI382019B (en) 2005-08-19 2013-01-11 Array Biopharma Inc Aminodiazepines as toll-like receptor modulators
TW201402124A (en) 2005-08-19 2014-01-16 Array Biopharma Inc 8-substituted benzoazepines as toll-like receptor modulators
WO2007049675A1 (en) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having inhibitory activity on hiv integrase
CA2625673A1 (en) 2005-10-27 2007-05-03 Merck & Co., Inc. Hiv integrase inhibitors
TW200811153A (en) 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
ME02258B (en) 2006-07-07 2015-12-31 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
CA2657287A1 (en) 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
CA2665538A1 (en) 2006-10-18 2008-04-24 Merck & Co., Inc. Hiv integrase inhibitors
TWI434849B (en) 2007-06-29 2014-04-21 Gilead Sciences Inc Modulators of toll-like receptor 7
NZ585226A (en) 2007-11-16 2012-08-31 Gilead Sciences Inc Inhibitors of human immunodeficiency virus replication
JP5564435B2 (en) 2008-01-08 2014-07-30 メルク・シャープ・アンド・ドーム・コーポレーション Process for producing N-substituted hydroxypyrimidinone carboxamide
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
AU2009228398B2 (en) 2008-03-24 2014-07-03 Medivation Technologies, Inc. Pyrido [3, 4-b] indoles and methods of use
WO2009132135A1 (en) 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
WO2009154870A1 (en) 2008-05-05 2009-12-23 Merck & Co., Inc. Hiv integrase inhibitors
ES2408654T3 (en) 2008-07-02 2013-06-21 Avexa Limited Thiazopyrimidinones and their use
WO2010011819A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
DK2320908T3 (en) 2008-07-25 2014-03-10 Viiv Healthcare Co DOLUTEGRAVIR prodrugs
WO2010011815A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
ES2395705T3 (en) 2008-07-25 2013-02-14 Glaxosmithkline Llc Chemical compounds
WO2010011818A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
CN105198804B (en) 2008-07-25 2018-03-23 盐野义制药株式会社 Compound as hiv integrase inhibitor
EP2313111B1 (en) 2008-08-01 2013-09-04 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
EA201170537A1 (en) 2008-10-06 2011-12-30 Мерк Шарп Энд Домэ Корп. HIV INTEGRASE INHIBITORS
SG172060A1 (en) 2008-12-09 2011-07-28 Gilead Sciences Inc Modulators of toll-like receptors
JP5086478B2 (en) 2008-12-11 2012-11-28 塩野義製薬株式会社 Synthesis of carbamoylpyridone HIV integrase inhibitors and their intermediates
US20120022045A1 (en) 2009-01-28 2012-01-26 Shankar Venkatraman Bridged compounds as hiv integrase inhibitors
US8673307B1 (en) 2009-03-09 2014-03-18 The Rockefeller University HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
PT2444400T (en) 2009-06-15 2018-06-06 Shionogi & Co Substituted polycyclic carbamoylpyridone derivative
WO2011011483A1 (en) 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
US8691809B2 (en) 2009-08-18 2014-04-08 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
CN102781933B (en) 2009-08-18 2016-01-20 文蒂雷克斯药品公司 Substituted benzazepines as TOLL-like receptor modulators*
EP2470014A4 (en) 2009-08-26 2013-01-16 Merck Sharp & Dohme INHIBITORS OF HIV INTEGRASE
KR20120087916A (en) 2009-10-13 2012-08-07 엘랑코 애니멀 헬쓰 아일랜드 리미티드 Macrocyclic integrase inhibitors
CN102666541B (en) 2009-10-22 2015-11-25 吉里德科学公司 Derivatives of purines or deazapurines for use in the treatment, especially of viral infections
SMT201800290T1 (en) 2010-01-27 2018-07-17 Viiv Healthcare Co Antiviral therapy
AU2011221037A1 (en) 2010-02-26 2012-09-06 Japan Tobacco Inc. 1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine derivative and use of same as HIV integrase inhibitor
JP5739517B2 (en) 2010-04-02 2015-06-24 ヤンセン・アールアンドデイ・アイルランド Macrocyclic integrase inhibitor
US9216995B2 (en) 2010-04-12 2015-12-22 Shionogi & Co., Ltd. Pyridone derivative having integrase inhibitory activity
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
ES2634490T3 (en) 2010-07-02 2017-09-28 Gilead Sciences, Inc. Napht-2-ylacetic acid derivatives to treat AIDS
CA2802492C (en) 2010-07-02 2018-10-16 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
BR112013001553B1 (en) 2010-07-22 2021-01-12 Gilead Sciences, Inc. antiviral compounds for the treatment of paramyxoviridae infections and pharmaceutical compositions comprising them
PT3456721T (en) 2010-08-05 2021-05-04 Shionogi & Co Method of producing compounds having hiv integrase inhivitory activity
TWI577377B (en) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 Pharmaceutical composition
JP6092107B2 (en) 2010-10-01 2017-03-08 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッドＶｅｎｔｉＲｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． How to treat allergic diseases
NZ608673A (en) 2010-10-01 2015-04-24 Univ Pennsylvania Therapeutic use of a tlr agonist and combination therapy
WO2012058173A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
US8835411B2 (en) 2010-12-10 2014-09-16 Bristol-Myers Squibb Company HIV integrase inhibitors
MX346387B (en) 2011-01-12 2017-03-02 Ventirx Pharmaceuticals Inc Substituted benzoazepines as toll-like receptor modulators.
BR112013017947A2 (en) 2011-01-12 2018-12-18 Array Biopharma Inc substituted benzoazepines as toll-like receptor modulators
CN103608335B (en) 2011-04-08 2018-02-23 爱尔兰詹森科学公司 For treating the pyrimidine derivatives of virus infection
AP2013007249A0 (en) 2011-04-21 2013-11-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
EP3865507A1 (en) 2011-05-17 2021-08-18 The Rockefeller University Human immunodeficiency virus neutralizing antibodies and methods of use thereof
EA028254B1 (en) 2011-05-18 2017-10-31 Янссен Сайенсиз Айрлэнд Юси Quinazoline derivatives for the treatment of viral infections and further diseases
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (en) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 Antiviral compound
US9493549B2 (en) 2011-07-25 2016-11-15 The Rockefeller University Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
SMT201600476T1 (en) 2011-08-16 2017-03-08 Gilead Sciences Inc TENOFOVIR ALAFENAMIDE EMIFUMARATE
CN113264959A (en) 2011-10-07 2021-08-17 吉利德科学公司 Process for preparing antiviral nucleotide analogs
US9200009B2 (en) 2011-10-12 2015-12-01 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
US9695230B2 (en) 2011-12-08 2017-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein
EP2794613B1 (en) 2011-12-20 2017-03-29 Boehringer Ingelheim International GmbH Condensed triclyclic compounds as inhibitors of hiv replication
SG10201608528YA (en) 2011-12-21 2016-12-29 Novira Therapeutics Inc Hepatitis b antiviral agents
CN104245695B (en) 2012-02-08 2017-06-06 爱尔兰詹森科学公司 Piperidinyl pyrimidine derivatives for treating viral infection
US20150044137A1 (en) 2012-03-23 2015-02-12 The United States of America, as represented by the Secretary, Dep. of Health Care Human Services Neutralizing antibodies to hiv-1 and their use
PH12014500842A1 (en) 2012-04-20 2014-06-09 Gilead Sciences Inc Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
WO2014008636A1 (en) 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
EP2875024A4 (en) 2012-07-20 2015-12-23 Merck Sharp & Dohme AMIDO-SUBSTITUTED PYRIMIDINONE DERIVATIVES FOR USE IN THE TREATMENT OF HIV INFECTION
CN104781239B (en) 2012-08-10 2019-03-01 爱尔兰詹森科学公司 Alkylpyrimidine derivatives for the treatment of viral infections and other diseases
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
TR201807076T4 (en) 2012-10-10 2018-06-21 Janssen Sciences Ireland Uc Pyrrolo [3,2-d] pyrimidine derivatives for the treatment of viral infections and other diseases.
HUE051577T2 (en) 2012-10-18 2021-03-01 Univ Rockefeller Anti-HIV antibodies that provide broad neutralization
SG11201503042QA (en) 2012-11-16 2015-06-29 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
CN104955847A (en) 2012-12-04 2015-09-30 马里兰州大学(巴尔的摩) HIV-1 Env binding antibodies, fusion proteins and methods of use thereof
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
PE20151499A1 (en) 2012-12-21 2015-10-29 Gilead Sciences Inc POLYCYCLICAL CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE
WO2014104279A1 (en) 2012-12-27 2014-07-03 日本たばこ産業株式会社 SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR
EA035174B1 (en) 2013-02-21 2020-05-12 Янссен Сайенсиз Айрлэнд Юси 2-aminopyrimidine derivatives as modulators of toll-like receptors tlr7 and/or tlr8
TWI706945B (en) 2013-03-01 2020-10-11 美商基利科學股份有限公司 Therapeutic compounds for treating a retroviridae viral infection
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
EP2986291B1 (en) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
ES2656696T3 (en) 2013-05-17 2018-02-28 Merck Sharp & Dohme Corp. Condensed tricyclic heterocyclic compounds as inhibitors of HIV integrase
WO2014200880A1 (en) 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
EP3252058B1 (en) 2013-07-12 2021-01-20 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
NO2865735T3 (en) 2013-07-12 2018-07-21
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
US20160244510A1 (en) 2013-09-27 2016-08-25 Duke University Human monoclonal antibodies
AU2014324829B2 (en) 2013-09-27 2017-09-07 Merck Sharp & Dohme Corp. Substituted Quinolizine Derivatives useful as HIV integrase inhibitors
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2015117008A2 (en) 2014-01-31 2015-08-06 The Rockefeller University Broadly neutralizing anti-hiv antibodies and epitope therefor
NO2717902T3 (en) 2014-06-20 2018-06-23
WO2016014484A1 (en) 2014-07-21 2016-01-28 The Rockefeller University Combination of broadly neutralizing hiv antibodies and viral inducers
EP3196201B1 (en) 2014-08-22 2021-04-28 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
BR112017003663A2 (en) 2014-08-27 2017-11-28 Viiv Healthcare Uk No 5 Ltd compound, composition, and method for treating hiv infection.
EP3229804B1 (en) 2014-12-09 2020-05-06 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2016090545A1 (en) 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrate inhibitors
TWI695003B (en) 2014-12-23 2020-06-01 美商基利科學股份有限公司 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
TWI770552B (en) 2014-12-24 2022-07-11 美商基利科學股份有限公司 Quinazoline compounds
SG11201705184PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Isoquinoline compounds for the treatment of hiv
EP3237414B1 (en) 2014-12-24 2019-05-08 Gilead Sciences, Inc. Fused pyrimidine compounds for the tratment of hiv
US11071783B2 (en) 2015-03-19 2021-07-27 Duke University HIV-1 neutralizing antibodies and uses thereof
DK3271389T3 (en) 2015-03-20 2020-04-27 Us Health NEUTRALIZING ANTIBODIES AGAINST GP120 AND USE THEREOF
EP3285582B1 (en) 2015-03-26 2020-11-11 Merck Sharp & Dohme Corp. Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
KR20190057158A (en) 2015-04-02 2019-05-27 길리애드 사이언시즈, 인코포레이티드 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CN115109158A (en) 2015-05-07 2022-09-27 阿吉纳斯公司 anti-OX 40 antibodies and methods of use thereof
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
JP2018527366A (en) 2015-09-15 2018-09-20 ギリアード サイエンシーズ， インコーポレイテッド Toll-like receptor modulators for treating HIV
WO2017087257A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
WO2017087256A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors
EP3383431A4 (en) 2015-12-02 2019-08-28 Agenus Inc. ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE
MA43389A (en) 2015-12-02 2021-05-12 Agenus Inc ANTI-OX40 ANTIBODIES AND PROCESSES FOR USE
WO2017096276A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
TW202134282A (en) 2015-12-02 2021-09-16 美商艾吉納斯公司 Antibodies and methods of use thereof
WO2017096221A1 (en) 2015-12-02 2017-06-08 The Rockefeller University Bispecific anti-hiv broadly neutralizing antibodies
AU2016364891A1 (en) 2015-12-03 2018-06-07 Agenus Inc. Anti-OX40 antibodies and methods of use thereof
CN109311967B (en) 2015-12-15 2022-03-04 吉利德科学公司 human immunodeficiency virus neutralizing antibody
US10544155B2 (en) 2015-12-15 2020-01-28 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
CN107022027B (en) 2016-02-02 2022-03-08 中国疾病预防控制中心性病艾滋病预防控制中心 HIV-1 broad-spectrum neutralizing antibody and its use
CN107033241B (en) 2016-02-03 2022-03-08 中国疾病预防控制中心性病艾滋病预防控制中心 HIV-1 broad-spectrum neutralizing antibody and its use
EP4299133A3 (en) 2016-06-23 2024-03-13 VIIV Healthcare Company Compositions and methods for the delivery of therapeutics
PL3347352T3 (en) 2016-08-19 2019-12-31 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
JOP20190130A1 (en) 2016-12-02 2019-06-02 Merck Sharp & Dohme Tetracyclic heterocyclic compounds useful as integrated enzyme inhibitors for human immunodeficiency virus (HIV)
JP2020500866A (en) 2016-12-02 2020-01-16 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Tricyclic heterocyclic compounds useful as HIV integrase inhibitors
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
WO2018140368A1 (en) 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
JOP20180009A1 (en) 2017-02-06 2019-01-30 Gilead Sciences Inc Hiv inhibitor compounds
KR102324568B1 (en) 2017-06-21 2021-11-10 길리애드 사이언시즈, 인코포레이티드 Multispecific antibodies targeting HIV gp120 and CD3
US11833156B2 (en) 2017-09-22 2023-12-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
JOP20180092A1 (en) 2017-10-13 2019-04-13 Gilead Sciences Inc Hiv protease inhibitors
WO2019087016A1 (en) 2017-10-30 2019-05-09 Glaxosmithkline Intellectual Property Development Limited Compounds useful in hiv therapy
EP3752144B1 (en) 2018-02-15 2022-12-28 Merck Sharp & Dohme LLC Tricyclic heterocycle compounds useful as hiv integrase inhibitors
MA52367A (en) 2018-04-27 2021-03-03 Merck Sharp & Dohme USEFUL TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS
CN110526930B (en) 2018-05-23 2022-06-03 莫云芬 anti-HIV (human immunodeficiency virus) sulfur-containing polycyclic-hydroxypyridone formamide analogue and application thereof
CN112204029B (en) 2018-05-31 2024-03-01 豪夫迈·罗氏有限公司 therapeutic compounds
MA52802A (en) 2018-05-31 2021-04-14 Shionogi & Co POLYCYCLIC PYRIDONE DERIVATIVE
AR115455A1 (en) 2018-05-31 2021-01-20 Shionogi & Co POLYCLIC PYRIDOTRIAZINE DERIVATIVE
ES2989103T3 (en) 2018-06-05 2024-11-25 Merck Sharp & Dohme Llc Tricyclic heterocycle compounds useful as HIV integrase inhibitors
WO2019244066A2 (en) 2018-06-19 2019-12-26 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2020003093A1 (en) 2018-06-25 2020-01-02 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2020004443A1 (en) 2018-06-27 2020-01-02 国立大学法人北海道大学 Arenavirus growth inhibitor comprising polycyclic carbamoyl pyridone derivative
CR20200653A (en) 2018-07-03 2021-02-11 Gilead Sciences Inc ANTIBODIES TARGETING HIV GP120 AND METHODS OF USE
TWI829205B (en) 2018-07-30 2024-01-11 美商基利科學股份有限公司 Anti-hiv compounds
EA202190974A1 (en) 2018-10-22 2022-02-02 Борд Оф Риджентс Оф Зэ Юниверсити Оф Небраска ANTIVIRAL PRODRUGS AND THEIR NANO COMPOSITIONS
CN120535538A (en) 2018-11-29 2025-08-26 内布拉斯加大学董事会 Antiviral prodrugs and their nanoformulations
TW202544011A (en) 2019-03-22 2025-11-16 美商基利科學股份有限公司 Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
CN113795491B (en) * 2019-04-30 2024-09-03 上海拓界生物医药科技有限公司 Bridged ring-3, 4-dihydro-pyrido [1,2-a ] pyrazine-1, 8-dione compounds and pharmaceutical uses thereof
RU2717101C1 (en) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Anellated 9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine-7-carboxamides - integrase inhibitors, methods for preparing and using thereof
WO2021093846A1 (en) 2019-11-13 2021-05-20 上海拓界生物医药科技有限公司 Novel tetracyclic heterocyclic compounds and pharmaceutical use thereof
JP7776335B2 (en) 2019-11-28 2025-11-26 塩野義製薬株式会社 Polycyclic pyridopyrazine derivatives
TWI902729B (en) 2019-11-28 2025-11-01 日商鹽野義製藥股份有限公司 A medicament for the prevention and treatment of hiv infection, which is characterized by a combination of an integrase inhibitor and an anti-hiv drug
JP7453399B2 (en) 2020-02-24 2024-03-19 ギリアード サイエンシーズ， インコーポレイテッド Tetracyclic compounds and their use for treating HIV infection
KR20230079137A (en) 2020-09-30 2023-06-05 길리애드 사이언시즈, 인코포레이티드 Crosslinked Tricyclic Carbamoylpyridone Compounds and Uses Thereof
TW202227445A (en) 2020-10-30 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 Use of inhibiting genetically defective hiv virus
PL4196479T3 (en) 2021-01-19 2024-03-18 Gilead Sciences, Inc. Substituted pyridotriazine compounds and uses thereof
ES3048138T3 (en) 2021-02-16 2025-12-09 Merck Sharp & Dohme Llc Tetracyclic heterocycle compounds useful as hiv integrase inhibitors

Also Published As

Publication number Publication date
US20230339972A1 (en) 2023-10-26
SI4310087T1 (en) 2024-09-30
FI4310087T3 (en) 2024-08-09
CA3245817A1 (en) 2023-10-12
PL4310087T3 (en) 2024-11-04
JP7668428B2 (en) 2025-04-24
CL2025002304A1 (en) 2025-11-21
CL2025002302A1 (en) 2025-11-21
CR20240405A (en) 2024-11-28
HRP20240986T1 (en) 2024-11-08
EP4305034A1 (en) 2024-01-17
EP4310087A1 (en) 2024-01-24
NZ818531A (en) 2025-06-27
KR20250002321A (en) 2025-01-07
EP4305034B1 (en) 2024-06-12
ES2988416T3 (en) 2024-11-20
EP4438123A2 (en) 2024-10-02
AU2025201145B2 (en) 2025-03-13
PT4310087T (en) 2024-08-02
ES2992835T3 (en) 2024-12-18
LT4310087T (en) 2024-08-26
AU2025205450A1 (en) 2025-07-31
TWI856796B (en) 2024-09-21
EP4310087B1 (en) 2024-07-03
PL4305034T3 (en) 2024-10-14
PE20252272A1 (en) 2025-09-15
US20230339971A1 (en) 2023-10-26
PE20252269A1 (en) 2025-09-15
ZA202406990B (en) 2025-04-30
PT4305034T (en) 2024-06-25
TW202400165A (en) 2024-01-01
US12054496B2 (en) 2024-08-06
JP2025081461A (en) 2025-05-27
CL2024002988A1 (en) 2025-02-21
DK4310087T3 (en) 2024-07-15
IL315684A (en) 2024-11-01
JP2025510905A (en) 2025-04-15
CN120081853A (en) 2025-06-03
DOP2024000195A (en) 2025-03-31
CN118922419B (en) 2025-11-28
NZ814609A (en) 2025-05-02
HUE067768T2 (en) 2024-11-28
DK4305034T3 (en) 2024-07-01
TW202446773A (en) 2024-12-01
LT4305034T (en) 2024-07-10
TW202400172A (en) 2024-01-01
AU2023249631B2 (en) 2025-04-24
PE20250151A1 (en) 2025-01-16
AU2025201145A1 (en) 2025-03-06
FI4305034T3 (en) 2024-07-25
JP7668430B1 (en) 2025-04-24
CO2024013492A2 (en) 2024-10-31
TWI843506B (en) 2024-05-21
US20250115620A1 (en) 2025-04-10
CN118922419A (en) 2024-11-08
AU2023249631A1 (en) 2024-10-03
EP4438123A3 (en) 2024-12-04
SI4305034T1 (en) 2024-08-30
US12024528B2 (en) 2024-07-02
ZA202501263B (en) 2025-10-29
JP2025071130A (en) 2025-05-02
WO2023196875A1 (en) 2023-10-12
HRP20241051T1 (en) 2024-11-08
MX2024011695A (en) 2024-11-08

Similar Documents

Publication Publication Date Title
HUE067983T2 (en) Bridged tricyclic carbamoylpyridone compounds and uses thereof
IL319660A (en) Tricyclic compounds and their uses
SG11202109650XA (en) Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
IL304700A (en) Tetracyclic oxazepine compounds and uses thereof
GEP20247653B (en) Substituted tricyclic compounds
PT4065575T (en) Substituted tricyclic compounds
IL316531A (en) Compounds and uses thereof
IL289416B (en) Tricyclic compound and use thereof
IL288672A (en) Tricyclic compounds and their use
EP3956331A4 (en) Bicyclic and tricyclic compounds
ZA202303688B (en) Substituted tricyclic compounds
IL304819A (en) Tricyclic compounds and uses thereof
IL317807A (en) Polymorphic compounds and uses thereof
EP4495115A4 (en) Tetracyclic compound and use thereof
HK40097220A (en) Bridged tricyclic carbamoylpyridone compounds and uses thereof
IL315671A (en) Polymorphic compounds and uses thereof
HK40118684A (en) Tricyclic compounds and uses thereof
IL320688A (en) Tricyclic compounds
CA3270086A1 (en) Tricyclic compounds and their uses
HK40122692A (en) Tricyclic compounds and their uses
GB202208257D0 (en) Novel compounds and their uses
GB202208260D0 (en) Novel compounds and their uses
GB202318964D0 (en) Novel compounds and uses thereof
GB202307065D0 (en) Novel compounds and uses thereof
HK40067828A (en) Bicyclic and tricyclic compounds